Atossa Genetics Announces FDA Approval  of Endoxifen for "Expanded Access" as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient

Stock Information for Atossa Genetics Inc.

Loading

Please wait while we load your information from QuoteMedia.